Related Experiment Videos
Who benefits from hormone therapy?
1Department of Clinical Trial and Research, Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Japan.
Breast Cancer (Tokyo, Japan)
|June 7, 2006
Summary
Not all hormone receptor-positive tumors benefit from hormone therapy. This review discusses strategies like extended adjuvant therapy and new drug combinations to improve treatment effectiveness for breast cancer.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Hormone therapy is a cornerstone for hormone receptor (HR)-positive breast cancer, yet response varies significantly.
- Identifying non-responders is crucial for optimizing patient outcomes and avoiding ineffective treatments.
Purpose of the Study:
- To review current clinical trial outcomes regarding hormone therapy for HR-positive breast cancer.
- To discuss novel strategies aimed at enhancing hormone therapy efficacy and identifying responsive tumors.
Main Methods:
- Review of recent clinical trial data and scientific literature.
- Analysis of emerging therapeutic approaches and predictive biomarkers.
Main Results:
- Hormone therapy benefits are not universal for HR-positive tumors.
- New strategies including extended adjuvant therapy, array-based responder selection, and combination therapies show promise.
Conclusions:
- Distinguishing between highly hormone-responsive and less sensitive tumors is essential.
- Further research and clinical validation are needed to refine treatment selection and improve patient outcomes in HR-positive breast cancer.